Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia

Novel immunotherapies are changing the treatment landscape for patients with acute lymphoblastic leukemia (ALL). Specifically, chimeric antigen receptor (CAR) T-cell therapy results in response rates up to 90% in patients with previously refractory disease. We will review the U.S. Food and Drug Administration approved CAR T therapies in ALL, as well as the unique considerations for CAR T manufacture, administration, and toxicity profile. Finally, we will review CAR T products targeting antigens other than CD19, and allogeneic CAR T products under investigation.